Citations

1. (2003). Amino N: Autoantibodies against muscarinic cholinergic receptor in chronic fatigue syndrome.
2. (2002). Antinuclear autoantibodies (ANA) in Gulf War-related illness and chronic fatigue syndrome (CFS) patients. Clin Exp Immunol
3. (2006). B cell targeted therapies: safety considerations. J Rheumatol Suppl
4. (1997). BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol
5. (2006). Bleijenberg G: Chronic fatigue syndrome. Lancet
6. (1991). Brincker H: MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. A phase II study. Acta Oncol
7. (2005). Chronic fatigue syndrome is associated with diminished intracellular perforin. Clin Exp Immunol
8. (2006). Chronic fatigue syndrome.
9. (1996). EM: Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome.
10. (1997). EM: High frequency of autoantibodies to insoluble cellular antigens in patients with chronic fatigue syndrome. Arthritis Rheum
11. (2006). G: A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome. Qjm
12. (2008). Immunoassay with cytomegalovirus early antigens from gene products p52 and CM2 (UL44 and UL57) detects active infection in patients with chronic fatigue syndrome.
13. (2004). JT: IgM serum antibodies to Epstein-Barr virus are uniquely present in a subset of patients with the chronic fatigue syndrome. In Vivo
14. (2002). JT: IgM serum antibodies to human cytomegalovirus nonstructural gene products p52 and CM2(UL44 and UL57) are uniquely present in a subset of patients with chronic fatigue syndrome. In Vivo
15. (2007). JT: Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up. In Vivo
16. (1994). Komaroff A: The chronic fatigue syndrome: a comprehensive approach to its definition and study.
17. (2005). Komaroff AL: Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression. Clin Exp Immunol
18. (2007). Koneru AO: Chronic fatigue syndrome: inflammation, immune function, and neuroendocrine interactions. Curr Rheumatol Rep
19. (2006). MJ: B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol
20. (2002). NM: Evidence for the presence of immune dysfunction in chronic fatigue syndrome. Clin Diagn Lab Immunol
21. (2004). Peakman M: High levels of type 2 cytokine-producing cells in chronic fatigue syndrome. Clin Exp Immunol
22. (1987). Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome.
23. (2006). Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum
24. (2005). Reeves WC: Evaluation of autoantibodies to common and neuronal cell antigens in Chronic Fatigue Syndrome. J Autoimmune Dis
25. (2009). Ricevuti G: Immunological aspects of chronic fatigue syndrome. Autoimmun Rev
26. (2007). Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.
27. (2007). Rituximab therapy in malignant lymphoma. Oncogene
28. (2008). St Clair EW, Tedder TF: B-lymphocyte contributions to human autoimmune disease. Immunol Rev
29. (2004). T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.
30. (2008). Toubi E: Rituximab: beyond simple B cell depletion. Clin Rev Allergy Immunol
31. (2004). Valagussa P: ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.